EPS of $2.40, up 10% from a year ago and above the FactSet consensus of $2.35. Revenue grew 4% to $124.30 billion, to top the FactSet consensus of $124.26 billion and extend its streak of top-line ...
The pharma major beat analysts' expectations in the fourth quarter of 2024, despite looming competition for its top heart drug Entresto. The watchdog blocked access to DeepSeek after the companies ...
Results that may be inaccessible to you are currently showing.